Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 31Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 19Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, B-Cell 11Neoplasms 10Recurrence 8Lymphoma, Mantle-Cell 7Lymphoma, T-Cell, Peripheral 6Leukemia 5Hematologic Diseases 5Sarcoma, Kaposi 3Neuroblastoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3HIV Infections 3Acquired Immunodeficiency Syndrome 3Wilms Tumor 2Small Cell Lung Carcinoma 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Burkitt Lymphoma 2Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1

Interventions

ibrutinib 3Rituximab 3Cyclophosphamide 3Bortezomib 3tetulomab tetraxetan lu-177 2ponatinib 2fludarabine 2cobomarsen 2Vorinostat 2Lutetium 2enzalutamide 1durvalumab 1cirmtuzumab 1acalabrutinib 1Vincristine 1Prednisone 1Lutetium-177 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Etoposide 1Doxorubicin 1Carboplatin 1CA-4948 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immune System Diseases × Vincristine × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡